Study to Explore the Effects of Two Hour Inhalation of Ultrafine Carbon Black Particles on Airway Inflammation in Asthmatics

Exclusion Criteria

• •Infections of the respiratory tract within the last month
• •Past or present disease which, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
• •Pathological findings in safety laboratory tests
• •Subjects with clinically relevant infection or known ongoing clinically relevant inflammatory process
• •Suspected hypersensitivity to any ingredients of the medication involved with bronchoscopy (bronchodilators, sedatives and local anaesthetics)
• •Specific immunotherapy (SIT) within two years prior to the study
• •Administration of oral, injectable, or dermal corticosteroids according to 9.2
• •Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment
• •Risk of non-compliance with study procedures
• •Participation in another clinical trial 30 days prior to enrolment
• •Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
• •Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., language problems, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study